Lundbeck
Danish multinational pharmaceutical company focused on medicines for disorders of the brain and central nervous system.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Lundbeck, formally H. Lundbeck A/S, is a Danish multinational pharmaceutical company specializing in the research, development, manufacture, marketing, and sale of medicines for neurological and psychiatric disorders. Its therapeutic scope includes depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, epilepsy, and other conditions affecting the brain and central nervous system. The company is headquartered in Copenhagen and is listed on the Copenhagen Stock Exchange under the ticker LUN.CO. Hans Lundbeck founded the business in 1915 as a trading company rather than as a conventional drug manufacturer. Its early activities included supplying machinery, aluminium foil, artificial sweeteners, photographic equipment, and other goods to the Danish market. Lundbeck entered pharmaceuticals in 1924 by importing medicines and cosmetics from European and American suppliers. During the late 1930s it began manufacturing its own medicinal products and established an internal research function. Operations continued during the Second World War, although shortages of raw materials constrained production. The company progressively shifted toward brain diseases after the introduction of Truxal, a chlorprothixene-based treatment for schizophrenia, in 1957. Although Lundbeck retained a broad agency and trading heritage for several decades, it increasingly concentrated on central-nervous-system medicines from the late 1970s through the 1980s. The 1989 launch of the antidepressant Celexa, containing citalopram, became an important foundation for Lundbeck's international expansion and reinforced its identity as a specialist CNS pharmaceutical company. Lundbeck has used acquisitions, licensing, and portfolio transactions to build its international commercial and research platform. It acquired Ovation in 2009, supporting its presence in the United States; sold a group of non-core products to Recordati in 2012; acquired Chelsea Therapeutics in 2014; bought Prexton Therapeutics in 2018; and announced the acquisition of Alder BioPharmaceuticals in 2019. In 2024 it agreed to acquire Longboard Pharmaceuticals, an American company developing an epilepsy medicine. These transactions reflect the company's strategy of concentrating resources on selected neurological and psychiatric disease areas. The company has approximately 5,600 employees, production facilities in Denmark, France, and Italy, and research centers in Denmark and the United States. Its products have been registered in more than 100 countries. Lundbeck is a member of the European Federation of Pharmaceutical Industries and Associations and the International Federation of Pharmaceutical Manufacturers and Associations. Its corporate identity is closely associated with specialist expertise in brain diseases rather than with a broad, diversified consumer-health portfolio. Lundbeck's history also includes substantial regulatory and ethical scrutiny. In 2013 the European Commission fined Lundbeck and several generic-drug manufacturers over agreements that delayed market entry for generic versions of citalopram. The company also faced criticism over Nembutal, a barbiturate formerly supplied in the United States and used in executions. Lundbeck introduced a restricted distribution system to prevent sales to prisons in states that carried out lethal-injection executions, and later transferred the product portfolio to Akorn while requiring continuation of the distribution restrictions. These episodes remain part of the public record surrounding the company, alongside its continuing focus on neurological innovation.
History
Lundbeck was established in 1915 by Hans Lundbeck as a Danish trading enterprise. Its original business supplied varied goods, including machinery, aluminium foil, artificial sweeteners, and photographic equipment. The company entered the pharmaceutical sector in 1924, initially importing medicines and cosmetics from European and American companies. By the late 1930s, Lundbeck had moved toward manufacturing its own medicinal products and had created an in-house research department. The Second World War limited output because of raw-material shortages, but the company continued operating. A major strategic turning point came with the 1957 introduction of Truxal, based on chlorprothixene and used in the treatment of schizophrenia. This product marked Lundbeck's increasingly direct involvement in medicines for brain disorders. The Lundbeck Foundation was established in 1954 to support and expand the Lundbeck Group and to fund scientific research. From the late 1970s through the 1980s, Lundbeck gradually withdrew from its former agency and trading activities and became a dedicated pharmaceutical company focused on central-nervous-system diseases. The 1989 launch of Celexa, the brand name for citalopram, was especially important. Celexa became a major product and helped drive international expansion, strengthening Lundbeck's position in antidepressants and establishing a platform for broader global commercialization. The company expanded its geographic and therapeutic reach through transactions and portfolio management. In 2009 it acquired Ovation, creating a stronger commercial platform in the United States. In 2012 it sold non-core products to Recordati, reflecting a decision to concentrate on strategic CNS medicines. Chelsea Therapeutics was acquired in 2014, followed by Prexton Therapeutics in 2018. Lundbeck announced the acquisition of Alder BioPharmaceuticals in 2019 and agreed to acquire Longboard Pharmaceuticals in 2024, continuing its emphasis on neurological disease and epilepsy-related opportunities. Lundbeck's corporate development has also been shaped by controversies. The company was criticized for the use of Nembutal, a pentobarbital product, in executions in the United States. It responded with a restricted distribution program intended to prevent supply to prisons in states using lethal injection, and in 2011 divested the relevant portfolio to Akorn with continuation of the restrictions. In another major episode, the European Commission fined Lundbeck in 2013 for agreements with generic manufacturers that delayed cheaper citalopram products. The case highlighted the commercial and regulatory risks associated with protecting pharmaceutical exclusivity. Today Lundbeck operates internationally, with approximately 5,600 employees, manufacturing sites in Denmark, France, and Italy, research centers in Denmark and the United States, and product registrations in more than 100 countries. The company presents itself as a specialist neuroscience pharmaceutical business rather than a general-purpose medicines conglomerate.
- 2024
Longboard Pharmaceuticals acquisition agreed
[1]Lundbeck agreed to acquire Longboard Pharmaceuticals, an American epilepsy-drug developer.
- 2019
Alder BioPharmaceuticals acquisition announced
[1]Lundbeck announced an agreement to acquire Alder BioPharmaceuticals for $18 per share.
- 2018
Prexton Therapeutics acquired
[1]Lundbeck acquired Prexton Therapeutics in a transaction valued at up to €905 million.
- 2014
Chelsea Therapeutics acquired
[1]Lundbeck acquired Chelsea Therapeutics in a transaction valued at up to $658 million.
- 2012
Non-core portfolio sold to Recordati
[1]Lundbeck sold a portfolio of non-core products to Recordati as part of its focus on strategic CNS medicines.
- 2009
Ovation acquired
[1]The acquisition of Ovation established a stronger commercial platform for Lundbeck in the United States.
- 1989
Celexa launched
[1]Lundbeck launched the antidepressant Celexa, based on citalopram, which became an important product for international expansion.
- 1957
Truxal launched
[1]The company introduced Truxal, a chlorprothixene treatment for schizophrenia, and entered the brain-disorders market.
- 1954
Lundbeck Foundation established
[1]The Lundbeck Foundation was created to support the group's activities and scientific research.
- 1924
Entry into pharmaceuticals
[1]Lundbeck began importing medicines and cosmetics from European and American suppliers.
Products and positioning
Specialist pharmaceutical company focused on research, development, and commercialization of medicines for brain and central-nervous-system disorders.
Antipsychotic medicine · 1957
Truxal
Truxal is Lundbeck's chlorprothixene-based medicine for schizophrenia. Introduced in 1957, it represented the company's early strategic move into treatments for brain disorders and helped establish its long-term focus on central-nervous-system pharmaceuticals.
Antidepressant · 1989
Celexa
Celexa is the brand name associated with citalopram, an antidepressant launched by Lundbeck in 1989. The product became a cornerstone of the company's international expansion and later generated significant competition and regulatory scrutiny when generic manufacturers sought market entry.
Barbiturate medicine
Nembutal
Nembutal is a pentobarbital product formerly supplied by Lundbeck in the United States. Because the drug was used in lethal injections, Lundbeck introduced a restricted distribution system and later divested the portfolio to Akorn while requiring continuation of the restrictions.
Controversies
2013
Citalopram generic-delay agreements
The European Commission fined Lundbeck €93.8 million after finding that agreements with generic-drug manufacturers delayed the entry of less expensive citalopram products. The Commission also fined several generic manufacturers.
2011
Nembutal and execution-use controversy
Lundbeck faced criticism because its pentobarbital product Nembutal was used in executions in the United States. The company adopted a specialty-pharmacy distribution program intended to prevent sales to prisons in states carrying out lethal-injection executions, then transferred the portfolio to Akorn under a continuing restriction arrangement.
Brand decisions
2024
Acquire Longboard PharmaceuticalsM&ABackground
Lundbeck continued to pursue growth in neurological disease, particularly epilepsy.
Action taken
The company agreed to acquire Longboard Pharmaceuticals.
Reported transaction value. $2.6 billion (2024)
2019
Acquire Alder BioPharmaceuticalsM&ABackground
Lundbeck sought to expand its neurological-medicine portfolio through an international acquisition.
Action taken
The company announced an offer of $18 per Alder share.
Reported transaction valuation. Almost $2 billion (2019)
2018
Acquire Prexton TherapeuticsM&ABackground
Lundbeck pursued assets in neurological disease.
Action taken
The company acquired Prexton Therapeutics for up to €905 million.
Maximum transaction value. €905 million (2018)
2014
Acquire Chelsea TherapeuticsM&ABackground
Lundbeck continued expanding its neurological and specialty-pharmaceutical portfolio.
Action taken
The company acquired Chelsea Therapeutics for up to $658 million.
Maximum transaction value. $658 million (2014)
2012
Refocus on strategic CNS productsStrategyBackground
Lundbeck aimed to concentrate resources on newer and strategically important central-nervous-system medicines.
Action taken
The company sold a portfolio of non-core products to Recordati.
Aftermath
The transaction narrowed the portfolio around Lundbeck's specialist neuroscience strategy.
2011
Restrict Nembutal distributionStrategyBackground
Criticism arose over the use of Nembutal in executions by US prisons.
Action taken
Lundbeck introduced an exclusive specialty-pharmacy drop-ship program designed to deny supply to prisons in states actively using lethal injection.
Aftermath
The restrictions were carried forward when the relevant portfolio was divested to Akorn in December 2011.
2009
Acquire OvationM&ABackground
Lundbeck sought to strengthen its commercial presence in the United States.
Action taken
The company acquired Ovation and established a US commercial platform.
Aftermath
The transaction supported Lundbeck's international commercialization strategy.
Recent events
- 2025
Lundbeck loses reported Avadel bidding contest[1]
M&A
Reference material reports that Lundbeck lost a bidding contest with Alkermes for Irish sleep-disorder drugmaker Avadel Pharmaceuticals.
- 2024
Lundbeck agrees to acquire Longboard Pharmaceuticals[1]
M&A
Lundbeck agreed to acquire American epilepsy-drug developer Longboard Pharmaceuticals in a transaction reported at approximately $2.6 billion.
- 2019
Lundbeck agrees to acquire Alder BioPharmaceuticals[1]
M&A
Lundbeck announced an agreement to acquire Alder BioPharmaceuticals at $18 per share, valuing the transaction at almost $2 billion.
- 2018
Lundbeck announces Deborah Dunsire as chief executive[1]
Leadership change
Deborah Dunsire, formerly chief executive of Millennium Pharmaceuticals, was announced as Lundbeck's new chief executive and president.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/lundbeck · Editorial policy · How profiles are compiled